We don’t know this yet but they did the testing to check for T-cell response and it was successful. No one else did this and the results have come in in the most successful vaccines thus far and they do not produce long term immunity… forget the Russian and China vaccines. So if GNBT/NGIO are available with maybe a bunch of new vaccines in the fall … they will be one of I would guess a few at most that produce long term immunity. But Joe predicted early last year that 95% of these either wouldn’t work or produce long term immunity. Going forward Joe said that In vivo results are usually better than Ex vivo … so I’m basing my comments on Joe’s prediction of In vivo results and the confluence of worldwide booster necessity and projected timeline for vaccine development. I think the most problematic is the vaccine timeline because of their track record with meeting deadlines or projected timelines
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links